A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
about
Tuberculosis vaccines and prevention of infectionChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesRecent advances in the development of vaccines for tuberculosisTuberculosis vaccine types and timingsTB vaccines; promoting rapid and durable protection in the lungNanoparticle approaches against bacterial infectionsAntibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Trial watch: Naked and vectored DNA-based anticancer vaccinesConjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic MechanismArterial Catheterization and Infection: Toll-like Receptors in Defense against Microorganisms and Therapeutic ImplicationsBeyond antigens and adjuvants: formulating future vaccines.Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidatesCombination of TLR1/2 and TLR3 ligands enhances CD4(+) T cell longevity and antibody responses by modulating type I IFN production.Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling.Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.New findings of Toll-like receptors involved in Mycobacterium tuberculosis infection.Synthetic nanovaccines for immunotherapy.Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice.Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune ResponsesTargeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves
P2860
Q26782022-DD3D6B4C-B3FF-4ADB-9D47-49B775C72A45Q26783488-3621D256-CC30-4876-9D7B-7116F6EB3DD4Q26796440-0FA00352-DA26-4CE7-B904-6C53960A33EBQ26862762-4884CA0E-F60F-4CE0-993E-5C0545B31BC6Q27007497-6FC76454-3E76-4F1F-8C14-57D0F945DC42Q34339159-83A3AE52-962B-4BFC-A7CE-423A1A5A7CF1Q34447679-F78DA369-5B7F-40FB-AB6F-9FD32A0F72B3Q35798986-8F700D80-C6BD-4E13-81C6-C5EE6E0BDBF1Q35843039-5DEB194E-E706-473F-BD19-03969C33D386Q36075279-47B918A2-19ED-481E-B255-1712A181BFFEQ36437035-3A2CDE31-A8D3-4FFF-A0EC-8BEE2FBB5184Q36618500-74F7E4B9-F20D-44A9-ABA3-EE35964C6D54Q36909492-FC289E5F-51D5-48CA-9A29-E34B2066EC0DQ37223530-18A728C6-4A28-4787-9700-61879A755B4EQ38907507-5717B262-DC12-499E-AD37-4B429E916AB0Q40076470-34D4C5C3-7107-420E-91CD-B30BC405122BQ40089069-397B1CB4-B4E9-4F1D-BE60-4BE4673F445DQ40131760-79FE60CB-24E9-417C-BE61-16F33D96CE43Q40280801-DDD2D9CC-D989-47C2-AC25-C1A93E1521B4Q40791130-89596BE4-2076-4378-82B1-C6AC5BB860B4Q55669579-EA73AC7F-F9CC-4EAA-8425-FC29AD298AF2Q55691134-62EB472C-A73A-465B-8151-225E1B8721DEQ56944933-F2253B34-6B75-4F68-89F6-1CC0C54E3C78Q58494322-2A52467E-48B8-483B-8527-1094323F3716
P2860
A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@en
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@nl
type
label
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@en
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@nl
prefLabel
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@en
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@nl
P2093
P2860
P50
P1433
P1476
A dual TLR agonist adjuvant en ...... rculosis vaccine antigen ID93.
@en
P2093
Elyse A Beebe
James J Moon
Rhea N Coler
Thomas E Hudson
P2860
P304
P356
10.1371/JOURNAL.PONE.0083884
P407
P577
2014-01-03T00:00:00Z